Literature DB >> 29939231

Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis With Endoscopically Normal Mucosa.

Ryo Ozaki1,2,3, Taku Kobayashi1, Shinji Okabayashi1, Masaru Nakano2, Shojiroh Morinaga4, Atsuko Hara4, Makoto Ohbu4, Kentaro Matsuoka4, Takahiko Toyonaga1,2, Eiko Saito1, Tadakazu Hisamatsu3, Toshifumi Hibi1.   

Abstract

BACKGROUND AND AIMS: The current goal of treatment for ulcerative colitis [UC] is endoscopic and ultimately histological mucosal healing. However, there is no consensus on the definition of histological mucosal healing. We evaluated histological risk factors for clinical relapse in UC patients with endoscopically normal mucosa to focus on the importance of histological evaluation.
METHODS: Patients with UC who underwent colonoscopy confirming Mayo endoscopic subscore [MES] ≤ 1 with biopsies were enrolled into this retrospective cohort. Three expert pathologists evaluated the presence or absence of chronic inflammatory cell infiltrate, breaches in the surface epithelium, crypt abscesses, mucin depletion, crypt architectural irregularities and basal plasmacytosis. Clinical relapse was defined as partial Mayo score ≥ 3 or modification of induction treatment. Prediction models of clinical relapse were generated, especially in patients with MES 0.
RESULTS: A total of 194 UC patients were enrolled. Histological abnormalities existed more frequently in patients with MES 1 than those with MES 0, while the vast majority of patients still possessed at least one abnormality. There was no significant difference in time to relapse between MES 0 and 1. Crypt architectural irregularities and mucin depletion were associated with time to relapse in patients with MES ≤ 1. In patients with MES 0, the presence of mucin depletion was the only factor significantly and independently associated with the risk of relapse (hazard ratio, 2.18 [1.16-5.82]; p = 0.03).
CONCLUSIONS: Mucin depletion was shown to be a histological risk factor for clinical relapse in UC patients with MES 0.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29939231     DOI: 10.1093/ecco-jcc/jjy092

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  17 in total

1.  Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission.

Authors:  Kelly C Cushing; William Tan; David H Alpers; Vikram Deshpande; Ashwin N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2019-11-07       Impact factor: 8.171

Review 2.  Mucosal healing in inflammatory bowel disease: Expanding horizon.

Authors:  Jimil Shah; Manik Lal Thakur; Usha Dutta
Journal:  Indian J Gastroenterol       Date:  2019-04-29

3.  Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Authors:  Hyuk Yoon; Sushrut Jangi; Parambir S Dulai; Brigid S Boland; Larry J Prokop; Vipul Jairath; Brian G Feagan; William J Sandborn; Siddharth Singh
Journal:  Gastroenterology       Date:  2020-06-22       Impact factor: 22.682

4.  UEG Week 2020 Poster Presentations.

Authors: 
Journal:  United European Gastroenterol J       Date:  2020-10       Impact factor: 4.623

5.  Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission.

Authors:  Hyuk Yoon; Sushrut Jangi; Parambir S Dulai; Brigid S Boland; Vipul Jairath; Brian G Feagan; William J Sandborn; Siddharth Singh
Journal:  Inflamm Bowel Dis       Date:  2021-07-27       Impact factor: 5.325

Review 6.  Evidence-based clinical practice guidelines for inflammatory bowel disease 2020.

Authors:  Hiroshi Nakase; Motoi Uchino; Shinichiro Shinzaki; Minoru Matsuura; Katsuyoshi Matsuoka; Taku Kobayashi; Masayuki Saruta; Fumihito Hirai; Keisuke Hata; Sakiko Hiraoka; Motohiro Esaki; Ken Sugimoto; Toshimitsu Fuji; Kenji Watanabe; Shiro Nakamura; Nagamu Inoue; Toshiyuki Itoh; Makoto Naganuma; Tadakazu Hisamatsu; Mamoru Watanabe; Hiroto Miwa; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-04-22       Impact factor: 7.527

7.  Environmental microcystin targets the microbiome and increases the risk of intestinal inflammatory pathology via NOX2 in underlying murine model of Nonalcoholic Fatty Liver Disease.

Authors:  Sutapa Sarkar; Diana Kimono; Muayad Albadrani; Ratanesh K Seth; Philip Busbee; Hasan Alghetaa; Dwayne E Porter; Geoff I Scott; Bryan Brooks; Mitzi Nagarkatti; Prakash Nagarkatti; Saurabh Chatterjee
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

8.  Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease?

Authors:  Olga Maria Nardone; Rosanna Cannatelli; Davide Zardo; Subrata Ghosh; Marietta Iacucci
Journal:  Therap Adv Gastroenterol       Date:  2019-07-18       Impact factor: 4.409

9.  Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse.

Authors:  Natsuki Ishida; Shunya Onoue; Takahiro Miyazu; Satoshi Tamura; Shinya Tani; Mihoko Yamade; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Takahisa Furuta; Ken Sugimoto
Journal:  Int J Colorectal Dis       Date:  2021-08-18       Impact factor: 2.571

10.  Relationship between Mayo endoscopic score and histological scores in ulcerative colitis: A prospective study.

Authors:  Jimil Shah; Usha Dutta; Ashim Das; Vishal Sharma; Harshal Mandavdhare; Pankaj Sharma; Dimple Kalsi; Priyanka Popli; Rakesh Kochhar
Journal:  JGH Open       Date:  2019-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.